ConclusionThis study seems to have found important new information for researchers and doctors working on treatments for pancreatic cancer. If doctors know the likely causal pathway of a particular tumour, they might be able to develop or choose a treatment known to work better for that pathway.But there’s a lot more work to do to prove the theory. This study is a starting point for new research to match particular treatments to particular classes of tumour. Although the researchers suggest some treatments already being tested in other areas might now be successfully targeted at the immunogenic type of tumour, we don’t yet know whether that will work. We need to see the results of clinical trials to test this idea. In addition, it’s unclear from the study whether there are new treatments that could be tested for all the subtypes of pancreatic cancer identified. We also don’t know how feasible it is for everyone with pancreatic cancer to have their tumours genome sequenced before treatment. So, while this study sounds like good news for the future treatment of pancreatic cancer, it may be a while before we know whether it’s the breakthrough being hailed in the media.   Links To The Headlines Major insight into killer pancreatic cancer. BBC News, February 24 2016Pancreatic cancer found to be four separate diseases. Mail Online, February 25 2016Researchers hail pancreatic cancer breakthrough which could revolutionise treatment of deadly disease. Daily Mirror, February …

Source: NHS News FeedCategory: Consumer Health News Tags: Cancer Genetics/stem cells Source Type: news

Related Links:

Conclusions—Cancer, occult and manifest, is associated with increased risks for stroke. The increased risk is linked mainly to cancers related to smoking.

Source: StrokeCategory: Neurology Authors: Tags: Epidemiology, Risk Factors, Cerebrovascular Disease/Stroke, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Dr. Chukwuemeka Ikpeazu at the Sylvester Comprehensive Cancer Center has brought hope — where once there was none — to patients in South Florida with unresectable pleural mesothelioma.
Ikpeazu is the principal investigator in the multicenter phase II clinical trial involving the much-anticipated immunotherapy drug durvalumab. Pharmaceutical giant AstraZeneca manufactures the drug under the brand name Imfinzi.
“I am optimistic, very, very optimistic that this drug will be effective for these patients,” Ikpeazu told “All the data, all the earlier studies, are encouraging.”

Authors: Shi J, Leng W, Zhao L, Deng C, Xu C, Wang J, Wang Y, Peng X
Conflicting results to identify the relationship between tooth loss and cancer risk. Therefore, a dose-response meta-analysis was performed to clarify and quantitative assessed the correlation between tooth loss and cancer risk. Up to March 2017, 25 observational epidemiological studies were included in current meta-analysis. Tooth loss was significantly associated with a higher risk of cancer. Additionally, tooth loss was associated with significantly a higher risk of esophageal cancer, gastric cancer, head and neck cancer, colorectal ca…

Source: OncotargetCategory: Cancer & Oncology Tags: Oncotarget Source Type: research

Authors: Qing L, Qing W
The epidermal growth factor receptor (EGFR) family are a series of important cancer therapeutic targets involved in cancer biology. These genes play an important role in tumor biological characteristics including angiogenesis, cell survival, invasion and glucose metabolism. In recent years, progresses have been achieved upon the cellular and molecular biological characteristics of EGFR and its role in cancer development based on the study of tumor specimens and experimental animal model. EGFR(HER1/ErbB) is overexpressed in over sixty percent of triple-negative breast cancers and occ…

Source: Minerva ChirurgicaCategory: Surgery Tags: Minerva Chir Source Type: research

AbstractWe assessed pancreatic cancer, lymphocyte infiltrates with a computational genomics approach. We took advantage of tumor-specimen exome files available from the cancer genome atlas to mine T- and B-cell immune receptor recombinations, using highly efficient, scripted algorithms established in several previous reports. Surprisingly, the results indicated that pancreatic cancer exomes represent one of the highest level yields for immune receptor recombinations, significantly higher than two comparison cancers used in this study, head and neck and bladder cancer. In particular, pancreatic cancer exomes have very large…

ConclusionLater weekday of surgery (Thursday or Friday) seems to influence the prognosis adversely for cancers of the gastrointestinal tract.

Source: British Journal of SurgeryCategory: Surgery Authors: Tags: Original article Source Type: research

ConclusionHigh variability and differences have been observed in survival among adults in Spain according to the type of cancer diagnosed, from above 84% to below 10%, reflecting high heterogeneity. The differences in prognosis by age, sex and period of diagnosis reveal opportunities for improving cancer care in Spain.

Authors: Willmer T, Cooper A, Peres J, Omar R, Prince S
T-box factors comprise an archaic family of evolutionary conserved transcription factors that regulate patterns of gene expression essential for embryonic development. The T-box transcription factor 3 (TBX3), a member of this family, is expressed in several tissues and plays critical roles in, among other structures, the heart, mammary gland and limbs and haploinsufficiency of the human TBX3 gene is the genetic basis for the autosomal dominant disorder, ulnar-mammary syndrome. Overexpression of TBX3 on the other hand has been linked to several cancers…

Source: BioScience TrendsCategory: Biomedical Science Tags: Biosci Trends Source Type: research

Cancer from smoking tobacco is considered dependent on mutagens, but significant molecular aspects of smoking‐specific, cancer development remain unknown. We defined sets of coding regions for oncoproteins, tumor suppressor proteins, and cytoskeletal‐related proteins that were compared between nonsmokers and smokers, for mutation occurrences, in the lung adenocarcinoma (LUAD), head and neck squamous carcinoma (HNSC), bladder carcinoma (BLCA), and pancreatic adenocarcinoma ( PAAD) datasets from the cancer genome atlas (TCGA). We uncovered significant differences in overall mutation rates, and in mutation rates …

Source: Physiological ReportsCategory: Physiology Authors: Tags: Original Research Source Type: research

This article is protected by copyright. All rights reserved

Source: Molecular CarcinogenesisCategory: Molecular Biology Authors: Tags: Brief Communication Source Type: research

Source link


Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image